Cite
HARVARD Citation
Morlock, R. et al. (n.d.). 658PPatient reported outcomes (PRO) results from phase II MONO and FAST zolbetuximab (IMAB362) trials in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma (GA/GEJA). Annals of oncology. p. . [Online].